Latest Conference Articles

July 6th 2013, 9:22am

ESMO Gastrointestinal Cancers Congress

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

July 6th 2013, 7:24am

ESMO Gastrointestinal Cancers Congress

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

July 6th 2013, 7:08am

ESMO Gastrointestinal Cancers Congress

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

July 5th 2013, 12:53pm

ESMO Gastrointestinal Cancers Congress

Ramucirumab significantly prolongs survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma following progression on first-line therapy.

July 5th 2013, 9:40am

ESMO Gastrointestinal Cancers Congress

Paul Ruff, MD, from the University of Witwatersrand, Johannesburg, South Africa, elaborates on factors that can be utilized to select an appropriate antiangiogenic therapy as a second-line treatment in metastatic colorectal cancer.

July 4th 2013, 10:24am

ESMO Gastrointestinal Cancers Congress

Treatment with weekly nab-paclitaxel plus gemcitabine remains a strong independent predictor of both OS and PFS in patients with metastatic pancreatic cancer compared with gemcitabine alone.

July 4th 2013, 8:38am

ESMO Gastrointestinal Cancers Congress

Patients who express low levels of a critical gene involved in transporting gemcitabine into pancreatic tumor cells have virtually no overall survival advantage from treatment with the drug in the adjuvant setting.

July 4th 2013, 5:36am

ESMO Gastrointestinal Cancers Congress

Alan P. Venook, MD, from the University of California, San Francisco, describes factors that contribute to the geographic variations seen in therapies utilized to treat cancer in the United States and Europe.

June 7th 2013, 7:04am

ASCO Annual Meeting

Salvage therapy combining the novel heat shock protein 90 inhibitor ganetespib with docetaxel significantly improved overall survival in some patients with non–small cell lung cancer.

June 6th 2013, 11:50am

ASCO Annual Meeting

Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.

June 4th 2013, 1:44pm

ASCO Annual Meeting

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

June 4th 2013, 1:25pm

ASCO Annual Meeting

Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.

June 4th 2013, 8:52am

ASCO Annual Meeting

A simple visual screening test using vinegar has the potential to dramatically reduce the number of deaths from cervical cancer in the developing world, according to findings from a large study in India, where use of the screening tool yielded a 31% reduction in cervical cancer mortality.

June 3rd 2013, 1:26pm

ASCO Annual Meeting

Shortages of cancer drugs caused many oncologists and hematologists to choose suboptimal treatment plans for their patients last year, and government efforts have done little to boost the availability of the hard-to-find medications.

June 3rd 2013, 12:29pm

ASCO Annual Meeting

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.

June 3rd 2013, 10:03am

ASCO Annual Meeting

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

June 3rd 2013, 7:40am

ASCO Annual Meeting

Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.

June 3rd 2013, 7:26am

ASCO Annual Meeting

Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

June 3rd 2013, 6:59am

ASCO Annual Meeting

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.

June 3rd 2013, 5:34am

ASCO Annual Meeting

Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.